Trial Profile
Safety and efficacy of FDC Ombitasvir/paritaprevir/ritonavir in patients with Hepatitis C virus infection who underwent maintenance Heamodialysis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 May 2018
Price :
$35
*
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 23 May 2018 New trial record